Merck & Co’s Kymera Therapeutics KYMR Stock Holding History

Merck & Co’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$64.3M	Hold	772,165	–	–	18.4%	3
2025 Q4	$60.1M	Hold	772,165	–	–	21.75%	3
2025 Q3	$43.7M	Hold	772,165	–	–	19.17%	3
2025 Q2	$33.7M	Hold	772,165	–	–	15.63%	3
2025 Q1	$21.1M	Hold	772,165	–	–	12.86%	3
2024 Q4	$31.1M	Buy	+772,165	New	+$34.9M	12.04%	3

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Merck & Co's KYMR Position: Q1 2026 in Review

Merck & Co held its Kymera Therapeutics (KYMR) position steady in Q1 2026 at 772,165 shares worth $64.3M. The position accounts for 18.4% of the portfolio, ranked #3.

Merck & Co first reported a position in KYMR in Q4 2024 and has held it in 6 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

Merck & Co held 772,165 shares of Kymera Therapeutics worth $64.3M as of Q1 2026.
Merck & Co left its Kymera Therapeutics share count unchanged in Q1 2026.
Kymera Therapeutics made up 18.4% of Merck & Co's portfolio in Q1 2026, its #3 holding.
Merck & Co first reported a position in Kymera Therapeutics in Q4 2024 and has held it in 6 quarters since.
256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Merck & Co's 13F filing for Q1 2026, filed 13 May 2026.